Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Subscribe To Our Newsletter & Stay Updated
